title: Pretransplant serum CXCL9 and CXCL10 levels fail to predict acute rejection in kidney transplant recipients receiving induction therapy.
authors.forename: Sebastiaan
authors.initials: S
authors.lastname: Heidt
authors.forename: Sushma
authors.initials: S
authors.lastname: Shankar
authors.forename: Anand S R
authors.initials: AS
authors.lastname: Muthusamy
authors.forename: David
authors.initials: D
authors.lastname: San Segundo
authors.forename: Kathryn J
authors.initials: KJ
authors.lastname: Wood
mesh_terms: D000208:Acute Disease; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D000077552:Basiliximab; D015415:Biomarkers / Q000097:blood; D054357:Chemokine CXCL10 / Q000097:blood*; D054370:Chemokine CXCL9 / Q000097:blood*; D006084:Graft Rejection / Q000097:blood / Q000276:immunology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000009:adverse effects*; D057234:Preoperative Period; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D015415:Biomarkers; C114753:CXCL10 protein, human; C080810:CXCL9 protein, human; D054357:Chemokine CXCL10; D054370:Chemokine CXCL9; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000074323:Alemtuzumab; D000077552:Basiliximab